"Farnesyltranstransferase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the synthesis of geranylgeranyl diphosphate from trans, trans-farnesyl diphosphate and isopentenyl diphosphate.
| Descriptor ID |
D051231
|
| MeSH Number(s) |
D08.811.913.225.437
|
| Concept/Terms |
Farnesyltranstransferase- Farnesyltranstransferase
- Farnesyltransferase
- Geranylgeranyl Pyrophosphatase
- Pyrophosphatase, Geranylgeranyl
- GGDP Synthase
- Synthase, GGDP
- GGPP Synthase
- Synthase, GGPP
- Farnesyl Diphosphate-Geranylgeranyl Diphosphate Synthase
- Farnesyl Diphosphate Geranylgeranyl Diphosphate Synthase
- Geranylgeranyl-Diphosphate Synthase
- Geranylgeranyl Diphosphate Synthase
- Synthase, Geranylgeranyl-Diphosphate
|
Below are MeSH descriptors whose meaning is more general than "Farnesyltranstransferase".
Below are MeSH descriptors whose meaning is more specific than "Farnesyltranstransferase".
This graph shows the total number of publications written about "Farnesyltranstransferase" by people in this website by year, and whether "Farnesyltranstransferase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Farnesyltranstransferase" by people in Profiles.
-
Fluvastatin Suppresses Mast Cell and Basophil IgE Responses: Genotype-Dependent Effects. J Immunol. 2016 Feb 15; 196(4):1461-70.
-
LMNA-associated cardiocutaneous progeria: an inherited autosomal dominant premature aging syndrome with late onset. Am J Med Genet A. 2013 Jul; 161A(7):1599-611.
-
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011 Mar 01; 17(5):1140-6.
-
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14; 113(20):4841-52.
-
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007 Feb 15; 109(4):1387-94.